Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Yeah, I know what you’re saying Doc. I guess until numbers rise again and concentrate everyone’s minds and wallets, at best it’s a waiting game … Although it’s the Covid combo with flu and RSV etc that creates havoc in hospitals - and we have great safety data at least. As Mani says maybe the repositioning is for the JV market and further potential there? But lack of clear direction slightly depressing for sure …
New covid waves plus flu and other respiratory viruses vvv likely on the horizon. Listening again to RM on Proactive, I think he is managing expectations about Covid-specific PTs which are in a quagmire of political-finance issues. But this is really a repositioning exercise underlining SNG’s use for the wider respiratory market as this is the bigger market share and because hospitals will be overflowing with multitude of respiratory patients this winter, including Covid patients and patients with Covid. Headlines will be all about overflowing hospitals and healthcare systems on the brink. So the wider respiratory trials are where it’s at because that’s now where the big opportunity lies. And that’s where Flic Gabbay’s expertise lies too …
Perhaps, but feels like management of our expectations today. It seems that without a big winter wave/ potent new variant (horrible things to wish for!) we are a bit stuck for now.
The questions I have for the board are:
Why are Activ 2 results so delayed? Is it due to no money due to politics? Are they waiting for full long covid results? Or has the study simply been shelved? And is outpatient option for SNG now off the table?
How likely is a winter hospital trial realistically now? Is Strive also delayed due to money/politics?
Was it you TommyD who wrote about interferon & Alzheimer’s? Did you see this?
https://www.ucl.ac.uk/news/2021/oct/alzheimers-and-covid-19-share-genetic-risk-factor
Jint’s Nature article talks about the same OAS1 gene and treatment with interferon. I’m thinking this could be why they think it could be of benefit for some long covid sufferers ……
On the tangent that received such vitriol earlier, here’s an interesting link between Jint’s latest paper and Alzheimer’s for some fun Thur night reading. I’m not suggesting anything here, so please no attacks!
https://www.ucl.ac.uk/news/2021/oct/alzheimers-and-covid-19-share-genetic-risk-factor
I’m interested in people’s thoughts about why Synairgen’s Activ-2 results haven’t been published yet. Seems very strange to me - a good 8 months on from passing stage 2. Obviously I'm hoping it’s because the results are great and the U.S. want to keep Synairgen for themselves and are waiting for funding … but suspect that is wishful thinking … What are the other possibilities?